women in the US. Estrogens play important roles in the growth and differentiation of normal mammary gland, as well as in the development and progression of breast carcinoma. Estrogens regulate gene expression via estrogen receptors, in which ER-a is expressed in about 70-80% of all breast cancers (Parl, 2000) . In current clinical practice, the presence of ERs is a marker for selecting hormonal or aromatase inhibitors treatment in patients with primary or recurred breast cancers (Mokbel, 2003) . Extensive studies have described that ERs are ligand-activated transcription factors that mediate the pleiotropic effects of the steroid hormone estrogen on the growth, development, and maintenance of several target tissues (Moggs and Orphanides, 2001) . Mechanisms by which ER mediates the transactivation of gene expression are complex. Hall et al. had summarized the following four pathways: (1) classical ligand-dependent pathway in which the ER complex regulates gene transcription through its interaction with ERE consensus DNA sequences; (2) ligand-independent pathway in which growth factors and their tyrosine kinase receptors may activate ER and increase the expression of ER target genes in the absence of estrogen; (3) DNA binding-independent pathway in which induction of gene regulation by ER complex is through interactions with no ERE-like promoter elements such as AP1, SP1, and CREs; (4) cell-surface (nongenomic) signaling in which estrogen activates a putative membrane-associated binding site that generates rapid tissue responses. However, the details of the estrogen effect on downstream gene targets, the role of cofactors, and crosstalk between other signaling pathways are still largely unknown.
Gene expression profiling technologies have empowered researchers to address complex questions in tumor biology. Many studies have shown the distinct patterns of gene expression related to ER status in breast cancer, and identified genes related to ER signaling (Gruvberger et al., 2001; West et al., 2001; Sotiriou et al., 2003) . However, most data were based on expression of mRNAs isolated from tumor masses, which constitute various cell populations such as stroma cells, fibroblasts, and lymphocytes, in addition to cancer cells. Moreover, the proportion of tumor cells in clinical samples varies significantly. These issues may compromise the gene expression data associated with ER that is expressed specifically on the epithelial cells. Laser capture microdissection (LCM) (Emmert-Buck et al., 1996) , a technique that procures histologically homogenous cell populations, has recently been successfully used in combination with DNA microarray technologies in studies of various types of tumors (Luo et al., 1999; Matsui et al., 2003; Yim et al., 2003; Nakamura et al., 2004) , including breast cancer for which genes were identified in association with tumor progression and metastasis Seth et al., 2003; Nishidate et al., 2004) . In order to gain insights into the mechanisms triggered by estrogen in breast epithelia cells, we applied LCM technique to a set of 28 early stage primary breast tumors that consisted of 17 ER-a þ and 11 ER-aÀ tumors. We then analysed their gene expression profiles using Affymetrix GeneChip Hu133A.
Breast tumors used in this study were selected from the Erasmus Medical Center tumor bank, Rotterdam, Netherlands. These samples were submitted to the laboratory for routine assessment of steroid hormone receptor status, and stored since in liquid nitrogen. The present study in which coded tumor tissues were used was performed according to the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands. The study was approved by the institutional Medical Ethical Committee of the Erasmus Medical Center. Patients were diagnosed as stage I and IIa between 1983 and 1994, with a median age of 49 years (range: 29-74 years). These breast tumors are mostly invasive ductal carcinoma (IDC) with a fraction of tumors having coexisting ductal carcinoma in situ (DCIS). Table 1 specified clinical characteristics of these patients. In all, 25 patients had breast-conserving surgery and three had mastectomy. All patients had dissection of the axillary lymph nodes. No neo-adjuvant or systemic adjuvant endocrine or chemotherapy had been administered. Tumors were characterized as primary invasive breast carcinoma with size less than 5 cm in diameter (pT1 or pT2). No lymph node metastasis was found at the time of surgery. ER status was determined by ligand-binding assay or enzyme immunoassay as described (Foekens et al., 1989) . To classify tumors as ER-a þ or ER-aÀ a cutoff of 10 fmol/mg cytosolic protein was used. To produce the gene expression profiles, an average of 1000 tumor cells were procured from fresh-frozen sections of the tumor block. A T7-based RNA linear amplification was carried out to obtain sufficient amounts of biotin-labeled aRNAs for microarray analysis (Kamme et al., 2004) . Using TargetAmp RNA amplification kit (Epicenter, WI) with the biotin-labeling step being substituted with Affymetrix Enzo kit (Affymetrix, CA, USA) in the second round of amplification, in average, 60 mg of aRNA was generated after two rounds of amplification, with a mean size distribution of approximately 2000 nucleotides. The amplification power was roughly 10 6 -fold from the initial total RNA. Linear regression analysis of the gene expression data derived from the replicates of amplified RNA indicated an R 2 value of 0.96 (data not shown). The good fidelity and reproducibility of two rounds T7-based RNA linear amplification have been demonstrated in several reports (Luzzi et al., 2003; Ma et al., 2003) , and amplification on the 3 0 end of transcripts does not have a major impact on the overall transcript profiles with Affymetrix GeneChip because the probe sets on the array are designed using 3 0 end sequences (Luzzi et al., 2003) . Furthermore, the amplification method was shown to enhance sensitivity of identifying the differentially expressed genes as compared to the unamplified method (Polacek et al., 2003) . To ensure that the amplification method in our study accurately preserves mRNA abundance in LCMderived RNA samples, the expression levels of 21 constitutively expressed housekeeping genes were compared between the LCM-procured samples and the bulk tumor samples (Figure 1 ). These 21 genes were selected based on a large collection of gene expression profiles from normal, benign, and tumor samples across different tissue types (data not shown). There is no statistically significant difference between the expression levels of these 21 genes from the two-round amplified LCM samples and their corresponding bulk tumor samples. Therefore, our result agrees with the published studies that two rounds of T7-based RNA amplification accurately preserve the mRNA abundance in the RNA samples, and the combination of LCM and RNA amplification is a reliable approach for gene expression profiling.
Gene expression intensities of approximately 23 000 probe sets on Affymetrix U133A chip were first normalized using a quantile normalization method, then ER-a-related genes and pathways F Yang et al filtered using 'present' call determined by Affymetrix MAS 5.0 software. An unsupervised two-dimensional hierarchical clustering algorithm was applied to the microarray data in order to group genes on the basis of similarities in the expression patterns and to cluster samples on the basis of similarities in the global gene expression profiles. As shown in Figure 2 , 56 samples (28 LCM þ 28 bulk tissue) were clustered into two major groups according to the source of RNA extraction: LCM-procured tumor cells and mixed cell population from bulk tumors. In each group, the samples were further clustered into two subgroups (group A and B in LCM samples, group C and D in bulk tissue samples).
As we investigated the possible association of clinical 1.00
1.00
1.00 Figure 1 Comparison of expression intensities of 21 consecutively expressed housekeeping genes between the bulk tumor data set and the LCM-procured sample data set. To generate the bulk tumor gene expression data, total RNA samples were extracted using Trizol method (Invitrogen, CA, USA). The targets were then biotin-labeled and hybridized to GeneChip Hu133A according to the manufactory's manual (Affymetrix, CA, USA). For the LCM-procured sample data set, tumor cells were procured using the PALM s Microlaser system and ZEISS Axiovert 135 (P.A.L.M. Microlaser Technologies, Germany) and an established protocol (Kamme et al., 2004) . In brief, frozen tumor specimens were cut as a series of 10-mm thick sections on a Cryocut 1800 Reichert-Jung cryotome (Cambridge Instruments, Germany) at a temperature between À171C to À251C, and were mounted on PEN (polyethylene naphthalate) membrane slides (P.A.L.M. Microlaser Technologies, Germany). Tissue sections were immediately fixed in 100% cold ethanol. For H&E staining, slides were sequentially dipped five times in a serial of ethanol solution with decreased concentration, 30 s in Harris hemotoxylin solution (Sigma, MO, USA), briefly washed with DI water, five times in Eosin Y (Sigma, St Louis, MO, USA), rinsed with 95% ethanol and 100% ethanol. Slides were ready for LCM procedure after 10 min of air dry. For each tumor sample, the first and the last tissue section were mounted on a glass slide and embedded in xylene after H&E staining, which severed as the reference and the confirmation for diagnosis. Areas containing tumor cells were then independently isolated from the slides and stored in 100% ethanol. Total RNA from laser-captured cells was extracted with RNeasy buffers (Qiagen, Germany) and recovered using Zymo spin-column (Zymo Research, CA, USA). The RNA samples were then amplified with TargetAmp kit with modifications as stated in the text. The final biotin-labeled aRNA product was hybridized to GeneChip Hu133A. For data analysis, the images from the scanned chips were processed using Microarray Analysis Suite 5.0 (Affymetrix Inc., CA, USA). Image data from each microarray was individually scaled to an average intensity of 600. Quality control standards were as follows: RawQ less than 4, background less than 100, scaling factor less than 4, and percentage of 'present' call was more than 35%. Blue and yellow bars represent expression levels in the bulk tumors and LCM samples, respectively. Error bars represent the standard deviation across 28 experiments in each data set. P-value was obtained using the t-test. P-value less than 0.01 were considered significantly different between the two data sets.
ER-a-related genes and pathways F Yang et al parameters to these subgroups, ER status has the most significant correlation with the classification. In the LCM data set, of 17 tumors diagnosed as ER-a þ , 15 were classified into the same subgroup (group A), and one formed its own subgroup and one being classified into ER-aÀ group. Of 11 ER-aÀ tumors, 10 were classified into subgroup B, with the estimated P-value of X 2 test being 0.0006. One ER-aÀ tumor was clustered with ER-a þ tumors. As for the bulk tumor data set, the same 15 ER-a þ samples were classified in the correct category (subgroup C), and the same single ER-aÀ sample was clustered with the ER-a þ group. The two ER-a þ tumors that were classified into ER-aÀ subgroup had very low expression of ER-a in the chip data, while the one ER-aÀ tumor that was classified with ER-a þ subgroup had high expression of ER-a on the chip. The discrepancy between the routine assessed ER status and the gene expression data may be due to the heterogeneity of tumors or the post-transcriptional regulation of ER expression in these tumors.
To identify genes associated with ER status and its related pathways, we carried out t-test between the ER-a þ subgroup and the ER-aÀ subgroup in each of the two data sets. Using the Bonferroni corrected P-value o0.05 as a cutoff, 175 probe sets representing 146 unique genes were found in the LCM-procured sample data set and 130 probe sets representing 112 unique genes were identified in the bulk tumor data set. By comparing these two gene lists, 61 genes were found to be common, 85 genes were unique to the LCMprocured samples, and 51 genes were only present in the bulk tumor samples (Figure 3a ; Supplementary information, Table I , II and III).
Of the 61 common genes, 36 were relatively overexpressed and 25 were downregulated in the ER-a þ subgroup (Supplementary information, Table I ). ER-a together with other genes, which have been demonstrated to be associated with ER-a þ tumors such as trefoil factors 1 and 3, GATA3, X-box-binding protein 1 (XBP1), and keratin 18, were among the upregulated genes (Perou et al., 2000; Gruvberger et al., 2001; van't Veer et al., 2002; Sotiriou et al., 2003; Weisz et al., 2004; Sun et al., 2005) . Gene regulated in breast cancer 1 (GREB1), which was upregulated in the ER-a þ Figure 2 Unsupervised two-dimensional hierarchical clustering analysis of the global gene expression data using Gene Spring software. A filter was applied to include genes that had 'present' calls in at least two samples. Each horizontal row represents a gene, and each vertical column corresponds to a sample. Red or green color indicates a transcription level above or below the median expression of the genes across all samples. Blue bars represent the LCM sample data and yellow bars represent the bulk tumor data. ER status of the patients determined by ligand-binding (LB) assay and/or enzyme immunoassay was represented as darker green blocks for ER-a þ patients and light green blocks for ER-aÀ patients. Bars A, B, C, and D represent major subgroups within the LCM and bulk tissue clusters.
ER-a-related genes and pathways
F Yang et al samples and had significant expression difference between the ER-a þ and ER-aÀ samples (P-value 1.2 Â 10
À6
), has been demonstrated to be an early response gene directly regulated by ER (Rae et al., 2005) . LRBA is an LPS-responsive and beach and anchor containing gene, and its expression is correlated with ER status and deregulation of LRBA expression will facilitate cancer cell growth (Wang et al., 2004) . P-cadherin (CDH3) was one of the 25 downregulated genes in the ER-a þ samples. It is expressed in the myoepithelial cells of breast, and its expression is associated with aberrant expression of ER-a and high histological grade and poor prognosis (Gamallo et al., 2001; Paredes et al., 2004) . Estrogen receptor b (ERb) was not among the 61 genes. By examining all the ERb probe sets represented on Affymetrix U133A chip, the ERb gene had very low expression (close to background level) in our sample population (data not shown). It had no significant difference between ER-a þ group and ER-aÀ group (P-value 0.52). It has been shown that ERb is primarily expressed in ovary, prostate, testis, spleen, lung, hypothalamus, and thymus, but is only expressed in a subset of breast tumors (Hall et al., 2001) .
Using Gene Ontology annotation, distinctive pathways were identified with P-value o0.05 for the three gene lists (Figure 3b-d) . For the 61 genes, the most significant pathway turned out to be the microtubule cytoskeleton organization pathway, followed by defense response, negative regulation of cell proliferation, glycolysis, digestion, vision, sodium ion-transport, iontransport, and morphogenesis pathways. The negative regulation of cell proliferation pathway, in which retinoic acid receptor responder (tazarotene induced) 1 and BTG family member 3 genes were found downregulated in ER-a þ tumors, has the most genes involved from the common gene list. An interesting discovery was the upregulation of the microtubuleassociated protein tau (MAPT), which was categorized in the microtubule cytoskeleton organization and biogenesis pathway, in ER-a þ breast tumors. This gene is differentially expressed in the nervous system (Binder et al., 1985) and its mutations resulted in several neurodegenerative disorders (Spillantini and Goedert, 1998) . Although its suppression in primate brains was reported in correlation with ingestion of phytoestrogen isoflavones (Kim et al., 2001) , its upregulation associated with ER status in breast tumor cells was not shown before.
The significant pathways identified in the LCM sample unique gene list were the following: glycosphingolipid biosynthesis, endocytosis, RAS protein Figure 3 Pathway analyses of differentially expressed genes between ER-a þ subgroup and ER-aÀ subgroup. Genes on Affymetrix Hu133A chip were mapped to the Biological Process categories of Gene Ontology (GO). The categories that had at least 10 genes on the chip were used for following pathway analyses. A list of genes that were selected from data analysis was mapped to the GO Biological Process categories. Then, hypergeometric distribution probability of the genes was calculated for each category. The categories that had a P-value less than 0.05 and at least two genes were considered over-represented in the selected gene list.
(a) Represents the pie chart of the number of genes designated to the three following categories: common in both LCM data set and bulk tumor data set; unique to the LCM sample data set; unique to the bulk tumor data set. ER-a-related genes and pathways F Yang et al signal transduction, central nervous system development, metabolism, and homophilic cell adhesion. UDP-glucose ceramide glucosyltransferase and UDP glycosyltransferase 8 are involved in glycosphingolipid biosynthesis such as ceramide, which functions as a second messenger to signaling cascades that promote differentiation, senescence, proliferation, and apoptosis (Simstein et al., 2003) . Although the mechanism under interactions with the ER pathway is unknown, ceramide generation was associated with tamoxifen-induced apoptosis (Mandlekar and Kong, 2001) , and possibly interrupts estrogen's antiapoptotic signaling pathways via the extracellular signal-regulated kinases (ERKs) (Chen et al., 2004) . Moreover, another identified pathway, endocytosis, has been associated with cell adhesion and migration in breast cancer via the Eph/Ephrin signaling pathway, which crossactivates the Jat-Stat pathway (Fox and Kandpal, 2004; Poliakov et al., 2004) . Members of the RAS oncogene family (RAB17 and RAB26) as well as genes involved in RAS protein signal transduction (SOS1 and PLD1) were identified. Hyperactive Ras can promote breast cancer growth and development, and affects upstream of the ERK/AKT signaling pathway (Eckert et al., 2004) . It was demonstrated in MCF7 cells that that Ras activity was required for nuclear export and degradation of p27 in response to estradiol and mediated a novel nongenomic pathway in promoting survival of breast cancer cells in culture (Fernando and Wimalasena, 2004) . Transforming growth factor b (TGF-b) has been demonstrated to have both tumor suppression and stimulating effects during early and late stages of tumorigenesis (Akhurst and Derynck, 2001) . The crosstalk between TGF-b signaling and estrogen signaling at DNA-dependent or -independent manners has been documented (Matsuda et al., 2001; Wu L et al., 2003; Ammanamanchi and Brattain, 2004) . A few genes that have implied action on TGF-b signaling were identified in the common and LCM unique gene lists. WW domain-containing protein 1 (WWP1), which is an E3 ubiquitin ligase expressed in epithelium (Malbert-Colas et al., 2003) , was found inhibiting TGF-b signaling through inducing ubiquitination and degradation of the TGF-b type I receptor (Komuro et al., 2004) . Sotiriou et al. also found this gene in their ER status associated gene list, although its interaction with ER pathway is still unknown. DACH1 was shown to inhibit TGF-b-induced apoptosis in breast cancer cell lines through binding Smad4 (Wu K et al., 2003) , which is a transcription corepressor for ER-a by interacting with the AF1 domain of ER-a (Wu L et al., 2003) . FOXC1, a regulator of DACH1 (Tamimi et al., 2004) , was also present in the LCM sample unique gene list. Upregulation of WWP1 and DACH1 suggested that TGF-b signaling was suppressed in ER-a þ tumors. Further in the LCM unique gene list, there are genes involved in functions that have been related to the ER pathway, such as DNA-depended transcription regulation, cell surface receptor-linked signal transduction, cell adhesion/motility, metabolic enzymes, and apoptosis. Among them, some genes are known to interact with ER, such as HDAC2, ANXA1, and CCNB1. Additional investigation of the potential roles of these genes and their relations with ER may provide insights of estrogen signaling and inter-relationships between these pathways.
On the other hand, for the genes that were unique to bulk tumor samples, pathways involved in chemotaxis and antimicrobial humoral response were ranked high. Cysteine-rich protein 1 (CRIP1) is produced in human peripheral blood mononuclear cells and is associated with host defense (Khoo et al., 1997) . Ladinin 1 (LAD1) is a basement-membrane protein that may contribute to the stability of the association of the epithelial layers with the underlying mesenchyme (Marinkovich et al., 1996) .
In summary, our approach in gene expression profiling using microscopically isolated breast tumor cells has not only identified differentially expressed genes related to ER status but also provided new information in potential pathways associated with estrogen signaling and additional genes for further investigation. The elucidation of the functional and clinical significance of these genes may be useful in our understanding of breast tumor development, and the identification of breast epithelia-specific genes may provide advantages in drug discovery for breast cancers.
